DrugPatentWatch Database Preview

Endo Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ENDO PHARMS INC, and what generic alternatives to ENDO PHARMS INC drugs are available?

ENDO PHARMS INC has five approved drugs.

There are fourteen US patents protecting ENDO PHARMS INC drugs.

There are two hundred and thirty-five patent family members on ENDO PHARMS INC drugs in forty-two countries and four supplementary protection certificates in four countries.

Summary for Endo Pharms Inc

International Patents:	235
US Patents:	14
Tradenames:	5
Ingredients:	5
NDAs:	5

Drugs and US Patents for Endo Pharms Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Endo Pharms Inc	MEGACE ES	megestrol acetate	SUSPENSION;ORAL	021778-001	Jul 5, 2005	AB	RX	Yes	Yes	9,107,827
Endo Pharms Inc	NASCOBAL	cyanocobalamin	SPRAY, METERED;NASAL	021642-001	Jan 31, 2005		RX	Yes	Yes	9,415,007
Endo Pharms Inc	MEGACE ES	megestrol acetate	SUSPENSION;ORAL	021778-001	Jul 5, 2005	AB	RX	Yes	Yes	9,040,088
Endo Pharms Inc	AVEED	testosterone undecanoate	INJECTABLE;INTRAMUSCULAR	022219-001	Mar 5, 2014		RX	Yes	Yes	7,718,640		Y
Endo Pharms Inc	NASCOBAL	cyanocobalamin	SPRAY, METERED;NASAL	021642-001	Jan 31, 2005		RX	Yes	Yes	7,879,349		Y
Endo Pharms Inc	MEGACE ES	megestrol acetate	SUSPENSION;ORAL	021778-001	Jul 5, 2005	AB	RX	Yes	Yes	6,592,903		Y
Endo Pharms Inc	MEGACE ES	megestrol acetate	SUSPENSION;ORAL	021778-001	Jul 5, 2005	AB	RX	Yes	Yes	9,101,540		Y

Expired US Patents for Endo Pharms Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Endo Pharms Inc	MEGACE ES	megestrol acetate	SUSPENSION;ORAL	021778-001	Jul 5, 2005	5,145,684

Paragraph IV (Patent) Challenges for ENDO PHARMS INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	250 mg/mL		2014-06-11
	Nasal Spray	500 mcg/spray		2017-04-28

International Patents for Endo Pharms Inc Drugs

Country	Patent Number	Estimated Expiration
Spain	2380318
Germany	602004001893
Norway	20054711
Japan	2005532352
European Patent Office	1551457
Japan	4460827
Eurasian Patent Organization	200401556

Supplementary Protection Certificates for Endo Pharms Inc Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0694547	C300071	Netherlands		PRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920
0694547	2002/028	Ireland		PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013
0694547	SPC/GB02/027	United Kingdom		PRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425
0694547	03C0003	France		PRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Endo Pharm
• Endo Pharms
• Endo Pharms Inc
• Endo Ventures Ltd